Lung cancer is the deadliest cancer worldwide, accounting for 1.82 million deaths in 2022. The second most deadly form of cancer is colorectum cancer, followed by liver cancer. However, lung cancer is only the sixth leading cause of death worldwide, with heart disease and stroke accounting for the highest share of deaths. Male vs. female cases Given that lung cancer causes the highest number of cancer deaths worldwide, it may be unsurprising to learn that lung cancer is the most common form of new cancer cases among males. However, among females, breast cancer is by far the most common form of new cancer cases. In fact, breast cancer is the most prevalent cancer worldwide, followed by prostate cancer. Prostate cancer is a very close second to lung cancer among the cancers with the highest rates of new cases among men. Male vs. female deaths Lung cancer is by far the deadliest form of cancer among males but is the second deadliest form of cancer among females. Breast cancer, the most prevalent form of cancer among females worldwide, is also the deadliest form of cancer among females. Although prostate cancer is the second most prevalent cancer among men, it is the fifth deadliest cancer. Lung, liver, stomach, colorectum, and oesophagus cancers all have higher deaths rates among males.

Lung cancer had the highest rate of death among all cancer types worldwide in 2022. In that year, there were around 17 deaths from trachea, bronchus and lung cancer per 100,000 population. The death rate for all cancers was 91.1 per 100,000 population. This statistic shows the rate of cancer deaths worldwide in 2022, by type of cancer.

In 2022, there were over 9.7 million cancer deaths worldwide. It is projected that the number of deaths due to cancer worldwide will increase to almost 18.5 million by 2050. The most prevalent type of cancer in 2022 was breast cancer with around 48 prevalent cases per 100,000 population. However, lung cancer is by far the deadliest type of cancer.

Lung Cancer Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. In 2022, around 1.82 million cancer deaths, or 19 percent of all cancer deaths worldwide were attributed to lung cancer. Long-term smoking is known to be a major cause of lung cancer. People who never quit smoking are 24 percent more likely to die before age 65 than people who never smoked in their lives.

Treatment In 2023, it was estimated that there were around 4,492 cancer immunotherapy products in R&D phases, as well as another 3,622 other cancer products in the R&D product pipeline. In the same year, it was projected that there were 965 active drugs for breast cancer, as well as 925 active drugs for non-small cell lung cancer.

For both sexes of all ages, the total number of cancer deaths was estimated to be approximately 9.74 million in 2022. Almost one fifth of these deaths were from lung cancer. This statistic describes the distribution of cancer deaths worldwide in 2022, sorted by type of cancer.

BackgroundUnderstanding the effects of demographic drivers on lung cancer mortality trends is critical for lung cancer control. We have examined the drivers of lung cancer mortality at the global, regional, and national levels.MethodsData on lung cancer death and mortality were extracted from the Global Burden of Disease (GBD) 2019. Estimated annual percentage change (EAPC) in the age-standardized mortality rate (ASMR) for lung cancer and all-cause mortality were calculated to measure temporal trends in lung cancer from 1990 to 2019. Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.ResultsDespite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. This increase was due to the changes in the number of deaths attributable to population aging (59.6%), population growth (56.7%), and non-GBD risks (3.49%) compared with 1990 data. Conversely, the number of lung cancer deaths due to GBD risks decreased by 19.8%, mainly due to tobacco (−12.66%), occupational risks (−3.52%), and air pollution (−3.47%). More lung cancer deaths (1.83%) were observed in most regions, which were due to high fasting plasma glucose levels. The temporal trend of lung cancer ASMR and the patterns of demographic drivers varied by region and gender. Significant associations were observed between the contributions of population growth, GBD risks and non-GBD risks (negative), population aging (positive), and ASMR in 1990, the sociodemographic index (SDI), and the human development index (HDI) in 2019.ConclusionPopulation aging and population growth increased global lung cancer deaths from 1990 to 2019, despite a decrease in age-specific lung cancer death rates due to GBD risks in most regions. A tailored strategy is needed to reduce the increasing burden of lung cancer due to outpacing demographic drivers of epidemiological change globally and in most regions, taking into account region- or gender-specific risk patterns.

Source: https://ourworldindata.org/cancer

The dataset titled "Cancer Types Causing Death," sourced from Our World in Data, provides a comprehensive overview of global cancer mortality trends. According to the dataset, lung cancer leads as the most fatal cancer worldwide, with approximately 1.8 million deaths in 2022, accounting for 18.7% of all cancer-related fatalities . Following lung cancer, colorectal cancer ranks second, causing about 900,000 deaths (9.3%), while liver cancer and breast cancer account for 760,000 (7.8%) and 670,000 (6.9%) deaths, respectively. Stomach cancer also remains a significant cause of death, with 660,000 fatalities (6.8%) .

The dataset highlights that lung cancer's prevalence is closely linked to tobacco use, particularly in regions like Asia. In contrast, breast cancer predominantly affects women, while colorectal cancer impacts both genders equally. Notably, the dataset indicates a decline in age-standardized death rates for certain cancers, such as stomach cancer, due to improved hygiene, sanitation, and antibiotic treatments targeting Helicobacter pylori infections . Our World in Data

Additionally, the dataset underscores the global disparity in cancer mortality, with approximately 70% of cancer deaths occurring in low- and middle-income countries . This disparity is attributed to factors like limited access to early detection, treatment, and preventive measures. The dataset serves as a valuable resource for understanding the global burden of cancer and the need for targeted public health interventions. World Health Organization

Serbia RS: Mortality Rate Attributed to Household and Ambient Air Pollution: Age-standardized: Female data was reported at 47.000 NA in 2016. Serbia RS: Mortality Rate Attributed to Household and Ambient Air Pollution: Age-standardized: Female data is updated yearly, averaging 47.000 NA from Dec 2016 (Median) to 2016, with 1 observations. Serbia RS: Mortality Rate Attributed to Household and Ambient Air Pollution: Age-standardized: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Serbia – Table RS.World Bank.WDI: Health Statistics. Mortality rate attributed to household and ambient air pollution is the number of deaths attributable to the joint effects of household and ambient air pollution in a year per 100,000 population. The rates are age-standardized. Following diseases are taken into account: acute respiratory infections (estimated for all ages); cerebrovascular diseases in adults (estimated above 25 years); ischaemic heart diseases in adults (estimated above 25 years); chronic obstructive pulmonary disease in adults (estimated above 25 years); and lung cancer in adults (estimated above 25 years).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

ObjectiveLung cancer is responsible for millions of deaths yearly, and its burden is severe worldwide. This study aimed to investigate the burden of lung cancer in the population of Wuhan based on the surveillance data from 2010 to 2019.MethodsData of this study was obtained from the Mortality Register System established by the Wuhan Center for Disease Control and Prevention. The study systematically analyzed the burden of lung cancer deaths in the population of Wuhan and its 13 administrative regions from 2010 to 2019 via the Joinpoint regression models, Age-Period-Cohort (APC) models, and decomposition analysis.ResultsThis study found the upward and downward trends in the age-standardized mortality rates (ASMRs) and age-standardized years of life lost rates (ASYLLRs) of lung cancer from 2010 to 2019. In Joinpoint regression models, the corresponding estimated annual percentage change (EAPC) were 1.00% and -1.90%, 0.60%, and -3.00%, respectively. In APC models, lung cancer mortality tended to increase with age for both sexes in Wuhan, peaking at the 85-89 age group; The period effects for different populations have started to gradually decline in recent years. In addition, the cohort effects indicated that the risk of lung cancer death was highest among those born in the 1950s-1955s, at 1.08 (males) and 1.01 (females). Among all administrative districts in Wuhan, the ASMR of lung cancer in the Xinzhou District has remained the highest over the study period. In decomposition analysis, both population aging (P

Introduction

Cancer Statistics: Cancer continues to be a major global health challenge, with significant increases in both incidence and mortality. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths worldwide. The most common cancers included lung, breast, colorectal, prostate, and stomach cancers. The global cancer burden is projected to rise substantially, with estimates suggesting 35.3 million new cases and 18.5 million cancer-related deaths by 2050.

This increase is attributed to factors such as population growth, aging, and exposure to risk factors like tobacco use, obesity, and environmental pollutants. The economic impact of cancer is also profound, with direct medical costs in the United States alone reaching nearly $209 billion in 2020.

These statistics underscore the urgent need for enhanced prevention, early detection, and treatment strategies to address the growing cancer burden globally. The information is presented from a market researcher's point of view, incorporating the latest data and trends.

Lung cancer was the cancer type with the highest rate of death among males worldwide in 2022. In that year there were around 25 deaths from trachea, bronchus and lung cancer among males per 100,000 population. The death rate for all cancers among males was 109 per 100,000 population. This statistic shows the rate of cancer deaths among males worldwide in 2022, by type of cancer.

Lung cancer is the number one cancer-related cause of death in Sweden and worldwide. In most countries, five-year survival estimates vary between 10% and 20% with evidence of improved survival over time. Over the last decades, the management of lung cancer has changed including the introduction of national guidelines, new diagnostic procedures and treatments. This study aimed to investigate temporal trends in lung cancer survival both overall and in subgroups defined by established prognostic factors (i.e., sex, stage, histopathology and smoking history). We estimated one-, two-, and five-year relative survival, and excess mortality, in patients diagnosed with squamous cell carcinoma or adenocarcinoma of the lung between 1995 and 2016 in Sweden. We used population-based information available in a national lung cancer research database (LCBaSe) generated by cross-linkage between the Swedish National Lung Cancer Register and several Swedish health and sociodemographic registers. We included 36,935 patients diagnosed with squamous cell carcinoma or adenocarcinoma of the lung between 1995 and 2016. The overall one-, two- and five-year survival estimates increased between 1995 and 2016, from 38% to 53%, 21% to 37%, and 14% to 24%, respectively. Over the study period, we also found improved survival in subgroups, for example in patients with stages III-IV disease, patients with adenocarcinoma, and never-smokers. The excess mortality decreased over the study period, both overall and in all subgroups. Lung cancer survival increased over time in the overall lung cancer population. Of special note was evidence of improved survival in patients with stage IV disease. Our results corroborate a previously observed global trend of improved survival in patients with lung cancer.

In 2022, the highest cancer rate for men and women among European countries was in Denmark with 728.5 cancer cases per 100,000 population. Ireland and the Netherlands followed, with 641.6 and 641.4 people diagnosed with cancer per 100,000 population, respectively.
Lung cancer Lung cancer is the deadliest type of cancer worldwide, and in Europe, Germany was the country with the highest number of lung cancer deaths in 2022, with 47.7 thousand deaths. However, when looking at the incidence rate of lung cancer, Hungary had the highest for both males and females, with 138.4 and 72.3 cases per 100,000 population, respectively.
Breast cancer Breast cancer is the most common type of cancer among women with an incidence rate of 83.3 cases per 100,000 population in Europe in 2022. Cyprus was the country with the highest incidence of breast cancer, followed by Belgium and France. The mortality rate due to breast cancer was 34.8 deaths per 100,000 population across Europe, and Cyprus was again the country with the highest figure.

As of 2022, the age-standardized mortality rate of lung cancer worldwide was **** per 100,000 population. At this time, the mortality rate of lung cancer was highest in Polynesia. This statistic shows the age-standardized mortality rate of lung cancer worldwide as of 2022, by region.

BackgroundLung cancer is a significant health concern in China. There is limited available data of its burden and trends. This study aims to evaluate the trends of lung cancer across different age groups and genders in China and the Group of Twenty (G20) countries, explore the risk factors, and predict the future trends over a 20-year period.MethodsThe data were obtained from the GBD study 2019. The number of cases, age standardized rate (ASR), and average annual percentage changes (AAPC) were used to estimate the trend in lung cancer by age, gender, region and risk factor. The trend of lung cancer was predicted by autoregressive integrated moving average (ARIMA) model by the “xtarimau” command. The joinpoint regression analysis was conducted to identify periods with the highest changes in incidence and mortality. Additionally, the relationship between AAPCs and socio-demographic index (SDI) was explored.ResultsFrom 1990 to 2019, both the incidence and mortality of lung cancer in China and G20 significantly increased, with China experiencing a higher rate of increase. The years with the highest increase in incidence of lung cancer in China were 1998-2004 and 2007-2010. Among the G20 countries, the AAPC in incidence and mortality of lung cancer in the Republic of Korea was the highest, followed closely by China. Although India exhibited similarities, its AAPC in lung cancer incidence and mortality rates was lower than that of China. The prediction showed that the incidence in China will continue to increase. In terms of risk factors, smoking was the leading attributable cause of mortality in all countries, followed by occupational risk and ambient particulate matter pollution. Notably, smoking in China exhibited the largest increase among the G20 countries, with ambient particulate matter pollution ranking second.ConclusionLung cancer is a serious public health concern in China, with smoking and environmental particulate pollution identified as the most important risk factors. The incidence and mortality rates are expected to continue to increase, which places higher demands on China’s lung cancer prevention and control strategies. It is urgent to tailor intervention measures targeting smoking and environmental pollution to contain the burden of lung cancer.

BackgroundThe exponential growth of the cancer burden attributable to metabolic factors deserves global attention. We investigated the trends of cancer mortality attributable to metabolic factors in 204 countries and regions between 1990 and 2019.MethodsWe extracted data from the Global Burden of Disease Study (GBD) 2019 and assessed the mortality, age-standardized death rate (ASDR), and population attributable fractions (PAFs) of cancers attributable to metabolic factors. Average annual percentage changes (AAPCs) were calculated to assess the changes in the ASDR. The cancer mortality burden was evaluated according to geographic location, SDI quintiles, age, sex, and changes over time.ResultsCancer attributable to metabolic factors contributed 865,440 (95% UI, 447,970-140,590) deaths in 2019, a 167.45% increase over 1990. In the past 30 years, the increase in the number of deaths and ASDR in lower SDI regions have been significantly higher than in higher SDI regions (from high to low SDIs: the changes in death numbers were 108.72%, 135.7%, 288.26%, 375.34%, and 288.26%, and the AAPCs were 0.42%, 0.58%, 1.51%, 2.36%, and 1.96%). Equatorial Guinea (AAPC= 5.71%), Cabo Verde (AAPC=4.54%), and Lesotho (AAPC=4.42%) had the largest increase in ASDR. Large differences were observed in the ASDRs by sex across different SDIs, and the male-to-female ratios of ASDR were 1.42, 1.50, 1.32, 0.93, and 0.86 in 2019. The core population of death in higher SDI regions is the age group of 70 years and above, and the lower SDI regions are concentrated in the age group of 50-69 years. The proportion of premature deaths in lower SDI regions is significantly higher than that in higher SDI regions (from high to low SDIs: 2%, 4%, 7%, 7%, and 9%). Gastrointestinal cancers were the core burden, accounting for 50.11% of cancer deaths attributable to metabolic factors, among which the top three cancers were tracheal, bronchus, and lung cancer, followed by colon and rectum cancer and breast cancer.ConclusionsThe cancer mortality burden attributable to metabolic factors is shifting from higher SDI regions to lower SDI regions. Sex differences show regional heterogeneity, with men having a significantly higher burden than women in higher SDI regions but the opposite is observed in lower SDI regions. Lower SDI regions have a heavier premature death burden. Gastrointestinal cancers are the core of the burden of cancer attributable to metabolic factors.

IntroductionLung cancer ranks the leading cause of cancer-related death worldwide. This retrospective cohort study was designed to determine time-dependent death hazards of diverse causes and conditional survival of lung cancer.MethodsWe collected 816,436 lung cancer cases during 2000-2015 in the SEER database, after exclusion, 612,100 cases were enrolled for data analyses. Cancer-specific survival, overall survival and dynamic death hazard were assessed in this study. Additionally, based on the FDA approval time of Nivolumab in 2015, we evaluated the effect of immunotherapy on metastatic patients’ survival by comparing cases in 2016-2018 (immunotherapy era, n=7135) and those in 2013-2016 (non-immunotherapy era, n=42061).ResultsOf the 612,100 patients, 285,705 were women, the mean (SD) age was 68.3 (11.0) years old. 252,558 patients were characterized as lung adenocarcinoma, 133,302 cases were lung squamous cell carcinoma, and only 78,700 cases were small cell lung carcinomas. TNM stage was I in 140,518 cases, II in 38,225 cases, III in 159,095 cases, and IV in 274,262 patients. 164,394 cases underwent surgical intervention. The 5-y overall survival and cancer-specific survival were 54.2% and 73.8%, respectively. The 5-y conditional survival rate of cancer-specific survival is improved in a time-dependent pattern, while conditional overall survival tends to be steady after 5-y follow-up. Except from age, hazard disparities of other risk factors (such as stage and surgery) diminished over time according to the conditional survival curves. After 8 years since diagnosis, mortality hazard from other causes became higher than that from lung cancer. This critical time point was earlier in elder patients while was postponed in patients with advanced stages. Moreover, both cancer-specific survival and overall survival of metastatic patients in immunotherapy era were significantly better than those in non-immunotherapy era (P

Despite lung cancer’s high mortality rate, many countries still lack organized lung cancer screening programs. This review aims to evaluate the impact of low-dose computed tomography (LDCT) screening on lung cancer diagnosis, mortality, and overall clinical outcomes. Following the Joanna Briggs Institute methodology for umbrella reviews, a comprehensive search was conducted in PubMed, Embase, and the Cochrane Library for reviews published between January 2013 and December 2023. Eligible meta-analyses included studies comparing LDCT screening with chest X-ray (CXR) or no screening, reporting outcomes such as sensitivity, specificity, and lung cancer mortality. The methodological quality of the included reviews was assessed using AMSTAR-2. Out of 801 citations, 14 meta-analyses met the inclusion criteria. LDCT demonstrated high sensitivity (0.97, 95% CI: 0.94–0.98) and specificity (0.87, 95% CI: 0.82–0.91). It significantly increased early-stage lung cancer detection (RR: 1.31, 95% CI: 1.18–1.45) and reduced lung cancer mortality by 18% (RR: 0.82, 95% CI: 0.75–0.90). However, the reduction in all-cause mortality (RR: 0.91, 95% CI: 0.75–1.06) was not statistically significant. Overdiagnosis and false positives remain essential challenges. This umbrella review confirms that LDCT screening effectively reduces lung cancer mortality, particularly in high-risk populations. Lung cancer was the most commonly diagnosed cancer worldwide in 2022, leading to over 2.5 million new cases and 1.8 million deaths. Although lung cancer has a high death rate, many countries still do not have screening programs in place to detect it early. This review examined the effectiveness of a special type of scan, known as low-dose computed tomography (LDCT), in detecting lung cancer early and saving lives. Researchers searched several major medical databases for studies published between 2013 and 2023. They focused on studies that compared LDCT scans with regular chest X-rays or no screening and checked the quality of the studies they included. Out of 801 studies found, 14 high-quality reviews were selected. The results showed that LDCT scans are very good at correctly detecting lung cancer. They helped find cancer earlier and reduced deaths from lung cancer by 18%. There were also concerns about finding cancers that may not have caused problems (overdiagnosis) and false alarms (false positives). In conclusion, LDCT screening can help save lives by detecting lung cancer early, especially in people at high risk, but some challenges need to be carefully managed.

United Kingdom UK: Mortality Rate Attributed to Household and Ambient Air Pollution: per 100,000 Population data was reported at 13.800 Ratio in 2016. United Kingdom UK: Mortality Rate Attributed to Household and Ambient Air Pollution: per 100,000 Population data is updated yearly, averaging 13.800 Ratio from Dec 2016 (Median) to 2016, with 1 observations. United Kingdom UK: Mortality Rate Attributed to Household and Ambient Air Pollution: per 100,000 Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s UK – Table UK.World Bank: Health Statistics. Mortality rate attributed to household and ambient air pollution is the number of deaths attributable to the joint effects of household and ambient air pollution in a year per 100,000 population. The rates are age-standardized. Following diseases are taken into account: acute respiratory infections (estimated for all ages); cerebrovascular diseases in adults (estimated above 25 years); ischaemic heart diseases in adults (estimated above 25 years); chronic obstructive pulmonary disease in adults (estimated above 25 years); and lung cancer in adults (estimated above 25 years).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

United States US: Mortality Rate Attributed to Household and Ambient Air Pollution: Age-standardized: Male data was reported at 17.000 NA in 2016. United States US: Mortality Rate Attributed to Household and Ambient Air Pollution: Age-standardized: Male data is updated yearly, averaging 17.000 NA from Dec 2016 (Median) to 2016, with 1 observations. United States US: Mortality Rate Attributed to Household and Ambient Air Pollution: Age-standardized: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Health Statistics. Mortality rate attributed to household and ambient air pollution is the number of deaths attributable to the joint effects of household and ambient air pollution in a year per 100,000 population. The rates are age-standardized. Following diseases are taken into account: acute respiratory infections (estimated for all ages); cerebrovascular diseases in adults (estimated above 25 years); ischaemic heart diseases in adults (estimated above 25 years); chronic obstructive pulmonary disease in adults (estimated above 25 years); and lung cancer in adults (estimated above 25 years).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.